IP Library Granted Patent US 12679867
Granted Patent B2
US 12679867 · App. 18/015,975 · Granted Jul 14, 2026

Polypeptide for preventing or treating idiopathic pulmonary fibrosis and pharmaceutical composition containing the same

Inventors: Choongseong Han (Seoul, KR); Donghun Woo (Seoul, KR); Minkyung Kim (Seoul, KR); Junghyuck Park (Seongnam-si, KR); Joonchul Kim (Seoul, KR); Geunho An (Seoul, KR)
Assignee: NEXEL CO., LTD.
C07K7/06A61P11/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12679867
App. No.
18/015,975
Granted
Jul 14, 2026
Kind
B2
Abstract

The present invention provides a polypeptide for preventing or treating idiopathic pulmonary fibrosis, which is synthesized by linking 9 to 10 amino acids together and comprises an amino acid sequence consisting of arginine (R, Arg)-glycine (G, Gly)-aspartic acid (D, Asp)-valine (V, Val)-phenylalanine (F, Phe)-proline (P, Pro)-serine (S, Ser)-tyrosine (Y, Tyr)-threonine (T, Thr). Accordingly, the polypeptide for preventing or treating idiopathic pulmonary fibrosis according to the present invention may restore lung function to normal by fundamentally treating lung tissue that has undergone fibrosis due to idiopathic pulmonary fibrosis, and furthermore, may delay or prevent the onset of idiopathic pulmonary fibrosis.

Claims (3)

1 . A polypeptide for treating idiopathic pulmonary fibrosis comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, wherein the polypeptide is 9-10 amino acids in length, and wherein the carboxy terminus of the amino acid sequence is —CONH 2 , wherein the polypeptide reduces expression of at least one of collagen and α-smooth muscle actin in lung tissue.

2 . The polypeptide of claim 1 , wherein the polypeptide is formulated for intralesional administration, intratracheal administration, or intravenous administration.

3 . A pharmaceutical composition for treating idiopathic pulmonary fibrosis, comprising the polypeptide of claim 1 as an active ingredient.